skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis

The journal of clinical endocrinology and metabolism, 2015-02, Vol.100 (2), p.363-370 [Peer Reviewed Journal]

Copyright © 2015 by the Endocrine Society ;Copyright © 2015 by The Endocrine Society ;Copyright © 2015 by the Endocrine Society 2015 ;ISSN: 0021-972X ;EISSN: 1945-7197 ;DOI: 10.1210/jc.2014-3421 ;PMID: 25590213

Full text available

Citations Cited by
  • Title:
    Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
  • Author: Domecq, Juan Pablo ; Prutsky, Gabriela ; Leppin, Aaron ; Sonbol, M. Bassam ; Altayar, Osama ; Undavalli, Chaitanya ; Wang, Zhen ; Elraiyah, Tarig ; Brito, Juan Pablo ; Mauck, Karen F ; Lababidi, Mohammed H ; Prokop, Larry J ; Asi, Noor ; Wei, Justin ; Fidahussein, Salman ; Montori, Victor M ; Murad, Mohammad Hassan
  • Is Part Of: The journal of clinical endocrinology and metabolism, 2015-02, Vol.100 (2), p.363-370
  • Description: Context: Various drugs affect body weight as a side effect. Objective: We conducted this systematic review and meta-analysis to summarize the evidence about commonly prescribed drugs and their association with weight change. Data Sources: MEDLINE, DARE, and the Cochrane Database of Systematic Reviews were searched to identify published systematic reviews as a source for trials. Study Selection: We included randomized trials that compared an a priori selected list of drugs to placebo and measured weight change. Data Extraction: We extracted data in duplicate and assessed the methodological quality using the Cochrane risk of bias tool. Results: We included 257 randomized trials (54 different drugs; 84 696 patients enrolled). Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg). Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg). For many other remaining drugs (including antihypertensives and antihistamines), the weight change was either statistically nonsignificant or supported by very low-quality evidence. Conclusions: Several drugs are associated with weight change of varying magnitude. Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed.
  • Publisher: Chevy Chase, MD: Endocrine Society
  • Language: English
  • Identifier: ISSN: 0021-972X
    EISSN: 1945-7197
    DOI: 10.1210/jc.2014-3421
    PMID: 25590213
  • Source: Geneva Foundation Free Medical Journals at publisher websites
    Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait